This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Deep Repetitive Transcranial Magnetic Stimulation Associated With Improved Social Functioning in a Young Woman With an Autism Spectrum Disorder
Enticott, P. G., Kennedy, H. A., Zangen, A., & Fitzgerald, P. B. (2011). The journal of ECT, 27(1), 41-43.
This case report examines the effect of Brainsway® Deep TMS (transcranial magnetic stimulation) in a patient with autism. In the case report, high-frequency stimulation was administered for 15 minutes per session, 9 treatments over 11 days. In this patient, social and interpersonal communications abilities were improved following treatment, as noted both by the patient and by her family. The conclusions were that Deep Transcranial Magnetic Stimulation in ASD can improves several facets of cortical dysfunction.